Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trc093
- Development stage
- Phase 1
- Lead developer
- TRACON Pharmaceuticals
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intravitreal
01
Overview
TRC093 is a first-in-class humanized recombinant IgG1 monoclonal antibody that targets multiple epitopes on denatured or cleaved collagens in the extracellular matrix. By binding to these cryptic collagen sites exposed during angiogenesis and tumor growth, TRC093 inhibits proteolytic collagen-mediated signaling pathways critical for tumor angiogenesis, tumor cell proliferation, and metastasis. The drug has demonstrated preclinical activity as monotherapy or in combination with chemotherapy in models of melanoma, breast cancer, and pancreatic cancer. It is being developed for oncology indications (solid tumors) as well as ophthalmology indications such as age-related macular degeneration (AMD)[1][2][4][5].
- Other names
- anti-denatured collagen monoclonal antibody trc093
02
Targets
COL (Collagen type XXI alpha 1 chain)
Beyond the preview
Go deeper on trc093.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trc093.